Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

Sponsor

Sanofi (Industry)

Overall Status

Completed

CT.gov ID

NCT01336751

Collaborator

(none)

212

Enrollment

Location

Arms

Duration (Months)

12.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Study Primary Objectives:

To compare glycemic control, as measured by hemoglobin A1c (A1C), between insulin glargine and 75% insulin lispro protamine suspension/25% insulin lispro as add-on therapies in subjects who failed oral combination therapy with sulfonylurea and metformin.

Study Secondary Objectives :

To compare the following measures between subjects receiving insulin glargine or 75% insulin lispro protamine suspension/25% insulin lispro:

Incidence of hypoglycemia
Change in weight
Change in serum lipid profile
Percentage of subjects achieving A1C levels ≤7%

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus, Type 2	Drug: Insulin glargine Drug: 75% insulin lispro protamine suspension and 25 % insulin lispro injection	Phase 3

Detailed Description

The planned duration of enrollment is 6 months. The study consists of 2 weeks screening phase and a study period that was planned to be 24 weeks.

Study Design

Study Type:

Interventional

Actual Enrollment :

212 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Lantus® (Insulin Glargine[rDNA Origin] Injection) vs Humalog® Mix 75/25 (75% Insulin Lispro Protamine Suspension and 25% Insulin Lispro Injection) as add-on Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and Glucophage (Metformin) Combination Treatment: a Randomized, Open, Parallel Study

Study Start Date :

Jul 1, 2001

Actual Primary Completion Date :

Dec 1, 2002

Actual Study Completion Date :

Dec 1, 2002

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Insulin glargine Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG). The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator.	Drug: Insulin glargine solution for subcutaneous injection Other Names: Lantus
Active Comparator: Lispro mix Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG). The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator.	Drug: 75% insulin lispro protamine suspension and 25 % insulin lispro injection suspension for subcutaneous injection Other Names: Humalog

Arm

Intervention/Treatment

Experimental: Insulin glargine

Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG). The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator.

Drug: Insulin glargine

solution for subcutaneous injection

Other Names:

Lantus

Active Comparator: Lispro mix

Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG). The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator.

Drug: 75% insulin lispro protamine suspension and 25 % insulin lispro injection

suspension for subcutaneous injection

Other Names:

Humalog

Outcome Measures

Primary Outcome Measures

Change from baseline in hemoglobin A1c (HbA1c) levels at week 24 [24 weeks]

Secondary Outcome Measures

Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) values ≤ 7.0% at Week 24 [24 weeks]
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) values ≤ 8.0% at Week 24 [24 weeks]
Change from baseline in fasting plasma glucose (FBG) values at week 24 [24 weeks]
Change from baseline in serum lipid values at week 24 [24 weeks]
Number and severity of hypoglycemic events and time of occurrence of hypoglycemic events [24 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 79 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients must have given their signed informed consent.
Males or females between 18 and 79 years of age.
Diagnosis of type 2 diabetes mellitus for at least one year.
Patients must have had continuous oral hypoglycemic treatment for at least three months using dosing of: at least half maximally labeled dose of sulfonylurea + at least 1000 mg metformin daily.
HBA1C ≥ 8 % and ≤11 %, inclusive, as measured at screening (visit 1).
Patients must have BMI of > 25 kg/m2 at baseline
Willingness to accept, and demonstrate ability to inject insulin glargine or 75% insulin lispro protamine suspension and 25% insulin lispro injection therapy.
Ability and willingness to perform SMBG profiles using a plasma glucose meter at least twice a day.
Patients must be able to understand and willing to adhere to and be compliant with the study protocol

Exclusion Criteria:

Patients, who have had stroke, MI, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) or angina pectoris within the last 12 months.
Patients with congestive heart failure requiring pharmacological treatment.
Patients on non-selective beta blockers (including ocular).
Patients with impaired renal function, as shown by but not limited to serum creatinine ≥ 1.5 mg/dl (133μmol/L) for males, or ≥ 1.4 mg/dl (124 μmol/L) for females.
Patients with acute infections.
Patients with diagnosis of dementia.
Treatment with systemic steroids or large doses of inhaled steroids.
Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis.
Patients with planned radiological examinations requiring administration of contrasting agents.
Clinical evidence of active liver disease, or serum ALT 2.5 times the upper limit of the normal range.
Patients with history of hypoglycemia unawareness.
Pregnant or lactating females.
Failure to use adequate contraception (women of current reproductive potential only).